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Abstract
The Epstein-Barr nuclear antigen 3C (EBNA3C), one of the essential latent antigens for Epstein-Barr virus (EBV)-induced
immortalization of primary human B lymphocytes in vitro, has been implicated in regulating cell proliferation and anti-
apoptosis via interaction with several cellular and viral factors. Gemin3 (also named DDX20 or DP103) is a member of DEAD
RNA helicase family which exhibits diverse cellular functions including DNA transcription, recombination and repair, and
RNA metabolism. Gemin3 was initially identified as a binding partner to EBNA2 and EBNA3C. However, the mechanism by
which EBNA3C regulates Gemin3 function remains unclear. Here, we report that EBNA3C directly interacts with Gemin3
through its C-terminal domains. This interaction results in increased stability of Gemin3 and its accumulation in both B
lymphoma cells and EBV transformed lymphoblastoid cell lines (LCLs). Moreover, EBNA3C promotes formation of a complex
with p53 and Gemin3 which blocks the DNA-binding affinity of p53. Small hairpin RNA based knockdown of Gemin3 in B
lymphoma or LCL cells remarkably attenuates the ability of EBNA3C to inhibit the transcription activity of p53 on its
downstream genes p21 and Bax, as well as apoptosis. These findings provide the first evidence that Gemin3 may be a
common target of oncogenic viruses for driving cell proliferation and anti-apoptotic activities.
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Introduction
Epstein-Barr virus (EBV) is the first identified human tumor
virus which causes infectious mononucleosis [1],[2], and is linked
several lymphoproliferative diseases [3], including Burkitt’s
lymphoma [4], nasopharyngeal carcinoma [5], and Hodgkin’s
disease [6]. EBV, a ubiquitous human c-herpesvirus, infects more
than 90% of the worldwide adult population. Moreover, AIDS
patients or post-transplant patients whose immune system is
suppressed have a high probability of developing EBV-associated
lymphomas. In vitro, EBV can transform normal resting human
B-cells to continuous proliferation of latently infected B cells
resulting in lymphoblastoid cell lines (LCLs). Like other herpes-
virus, the EBV life cycle exhibits both latent (non-productive) and
lytic (productive) phases. Four types of latency programs are
classified: Type I latency is mainly represented by Burkitt
lymphoma (BL) cells; there are two EBER genes expressed, the
BART transcripts, and EBNA1 (EBV nuclear antigen 1) [7]. Type
II latency is most frequently seen in Hodgkin’s lymphoma and
nasopharyngeal carcinoma with three additional latent-membrane
proteins, LMP-1, LMP-2A and LMP-2B expressed [8]. Latency
III is seen predominantly in lymphoproliferative diseases devel-
oped in immunocompromised individuals and EBV-transformed
lymphoblastoid cell lines [3] . In this group all six EBNAs, three
LMPs and the two EBERs are expressed [7],[9]. Type IV latency
is less strictly defined and is associated with infectious mononu-
cleosis patients [8],[9]. Some infected individuals is associated with
the tightly latent program (latency 0), in which latent gene
expression is almost undetectable [9]. The essential mediators for
EBV transformation of B lymphocytes and establishment of
latency in vitro include EBNA2, EBNA3A, 3C and LMP1
proteins. Importantly, EBNA3C plays a complex regulatory role
in the transcription of several viral and cellular genes. For
example, EBNA3C targets the cellular transcription factor RBP-Jk
to antagonize EBNA2 mediated transactivation [10],[11], and
cooperates with EBNA2 to activate the major viral LMP1
promoter via interaction with the cellular transcription factor,
Spi-1/Spi-B [12]. EBNA3C also regulates chromatin remodeling
by recruiting both histone acetylase and deacetylase activities [13–
15]. Furthermore, EBNA3C modulates the transcription of
cellular genes involved in cell migration and invasion by targeting
the metastasis suppressor Nm23-H1 [16]. In addition to its
transcriptional functions, it has been reported that EBNA3C has
cell-cycle regulatory functions, presumably mediated by direct
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c-Myc and interacts with Mdm2 in modulating p53 transcription
and apoptotic activities [20–22].
Gemin3 was discovered as a binding partner with EBV latent
antigens (EBNA2 and EBNA3C), and the survival motor neuron
(SMN) protein [23],[24]. It consists of 825 amino acids with 9
conserved motifs including the ASP-Glu-Ala-Asp motifs (or DEAD
box motif), and belongs to DExD/H RNA helicase family, which
plays many roles in RNA metabolism including pre-mRNA
splicing, ribosome biogenesis, RNA transport, translation initia-
tion, and RNA decay [24–28]. Both EBNA2 and EBNA3C
combine with Gemin3 and SMN,while EBNA2 cooperate with
SMN in transactivation of the viral LMP1 promoter [24–26]. It
has been shown that Gemin3 also interacts with and modulates a
variety of cellular transcription factors including steroidogenic
factor 1(SF-1) [29],[30], early growth response protein 2 (Egr2)
[31], forkhead transcription factor FOXL2 [32] , and mitogen Ets
repressor METS [33]. Although Gemin3 was shown to play a role
in gene transcription regulation, the function of Gemin3 in cell
proliferation remains largely unclear. Here we show that Gemin3
is stabilized by EBNA3C via protein-protein interaction and can
play a role in cell proliferation through formation of a complex
with p53 which results in blocking p53-mediated transcriptional
activity and apoptosis pathway. Knockdown of Gemin3 by RNA
interference dramatically increases apoptosis of EBV-infected
LCLs.
Results
EBNA3C forms a complex and co-localizes with Gemin3
in vivo
Similar to a screen by Grundoff, et al [24], a previous yeast two-
hybrid study showed that C-terminal domain of EBNA3C
interacts with Gemin3. To confirm that these two molecules do
associate in vivo, we performed co-immunoprecipitation assays to
determine if EBNA3C forms a complex with Gemin3 in EBV
transformed B lymphoma cell lines (LCL1 and LCL2). The B
lymphoma cell line Ramos which lacks EBNA3C expression
because it is EBV negative was used as a control. The results
showed that endogenous Gemin3 was dramatically immunopre-
cipitated by anti-EBNA3C antibody, but not by control mouse
serum (Figure 1A). The reverse immunoprecipitation with anti-
Gemin3 antibody further confirmed that EBNA3C does form a
complex with Gemin3 in vivo (Figure 1B). Since Gemin3 is
initially identified as a binding protein of EBNA2 and EBNA3C,
we wanted to determine if the EBNA3C complex with Gemin3
was independent of EBNA2 and performed similar coimmuno-
precipitation assays again by using the EBV negative B lymphoma
BJAB derived cell lines BJAB7 and BJAB10 with EBNA3C stable
expression alone. The results showed that EBNA3C alone was
sufficient to form a complex with Gemin3 in vivo (Figure 1C).
To determine if the association of EBNA3C and Gemin3 occurs
in the same cellular compartments in this scenario, we performed
immunofluorescence assays by ectopically expressing FLAG-
tagged EBNA3C and GFP-tagged Gemin3 in U2OS cells. The
immunofluorescence results showed that although EBNA3C
signals are shown as stippled, punctate dots with the exclusion of
nuclei, and Gemin3 signal was displayed as intense staining of
prominent but discrete foci in both nucleus and cytoplasm, and
there were a number of positions where co-localization staining of
EBNA3C with Gemin3 was evident (Figure 2A). To further
visualize the interaction of these two proteins under physiological
conditions, an EBV transformed cell line LCL1 was used.
Endogenous EBNA3C and Gemin3 signals were evident with
the co-localization pattern (Figure 2B), supporting the above data
that these two proteins can associate in the same complex.
Figure 1. EBNA3C forms a complex with Gemin3 in EBV
transformed cells. (A) and (B) Endogenous Gemin3 associates with
EBNA3C. Twenty million of Ramos, LCL1, and LCL2 cells were
individually lysed and subjected to immunoprecipitation (IP) with
EBNA3C (A10) or Gemin3 (12H12) specific antibody. 5% of whole cell
lysates (WCL) were loaded as input. Normal serum IgG was used for
preclear (PC). Lysates and IP complexes were resolved by SDS-PAGE and
subjected to western blotting (WB) with the indicated antibodies. (C)
Exogenous EBNA3C associates with Gemin3. The EBNA3C stable
expressing cells (BJAB7 and BJAB10) and parental BJAB cells were
individually lysed and subjected to immunoprecipitation (IP) and
western blotting as indicated.
doi:10.1371/journal.ppat.1002418.g001
Author Summary
Gemin3 (DDX20 or DP103) is a member of the DEAD-box
family of RNA helicases involved in various cellular
processes including DNA transcription and RNA process-
ing. The Epstein-Barr virus (EBV) encoded nuclear antigen
3C (EBNA3C) is essential for EBV-induced immortalization
of primary human B-lymphocytes in vitro. In this study, we
discovered that Gemin3 directly binds to the tumor
suppressor p53, and acts as a negative regulator blocking
p53 functions. Importantly, EBNA3C induces Gemin3
accumulation and enhances the formation of the complex
of Gemin3 and p53 in EBV- transformed primary human B
lymphocytes. Remarkably, inhibition of Gemin3 production
leads to cell death of B lymphoma cells, particularly
EBNA3C positive cells. This is the first evidence which
shows that Gemin3 directly impairs p53 function in EBV
positive cells, and that Gemin3 could be a potential target
for EBV-associated cancer therapy.
EBNA3C Stabilizes Gemin3
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domains
To define which domain of EBNA3C interacts with Gemin3,
we co-transfected HEK293 cells with expression constructs for
GFP-tagged Gemin3 and FLAG-tagged full-length (residues 1 to
992) or a series of truncated mutant of EBNA3C (1–365, 366–620,
or 621–992), and performed coimmunoprecipitation assays with
GFP or FLAG antibodies. Consistently, the results showed that
coimmunoprecipitation targeting Gemin3 or EBNA3C, always
results in Gemin3 co-immunoprecipitating with both the full-length
and C-terminal domain of EBNA3C with relatively high affinity
(Figure 3AandB).TofurtherdetermineiftheC-terminaldomainof
EBNA3C alone is sufficient to bind with Gemin3, we performed
GST pulldown assays by in vitro-translating the full length and
truncated mutants of EBNA3C followed by co-incubation with
bacterially expressed GST-Gemin3 protein. The results showed
that the C-terminal domain (621–992) of EBNA3C directly
interacted with Gemin3 (Figure 3C). Similarly, using in vitro-
translated Gemin3 coincubated with different bacterially expressed
GST-EBNA3C (1–365, 366–581, 582–792, and 900–992), we
further found that the C-terminal amino acids 621 to 792, a smaller
region than previously identified by yeast two-hybrid analysis (534–
778aa, [24]) of EBNA3C was critical for binding to Gemin3 in vitro
(Figure 3D and F). To determine the domainof Gemin3 responsible
for interacting with EBNA3C, we generated three truncated
mutants of GST-Gemin3 (residues 1–272, 307–547 and 546–825)
and performed GST pulldown assays with in vitro-translated full-
length EBNA3C. The result showed that Gemin3 bound with
EBNA3C via its C-terminal domain (Figure 3E and F), supporting
the previously identified data by yeast two-hybrid analysis [24], and
further narrows the interacting domain.
EBNA3C enhances the protein stability and production of
Gemin3
To determine if EBNA3C plays a role on the production of
Gemin3, we tested endogenous Gemin3 protein levels in EBNA3C
stable expressing cell lines (BJAB7 and BJAB10) and parental
BJAB cells, as well as EBV negative Ramos cells. Interestingly, the
results showed that EBNA3C greatly induced the production of
Gemin3 in BJAB cells (Figure 4A). To verify if whole EBV latent
infection with EBNA3C expression also has the same effect on
Gemin3 production, we did a western blot to detect Gemin3
protein levels in both PBMC and two EBV-infected derived LCL
cell lines. Consistent with EBNA3C expression alone, the results
showed that Gemin3 protein levels were significantly increased by
EBV infection (Figure 4B). The results of Gemin3 protein levels in
EBNA3C-knockdown BJAB10 and LCL cells were consistently
much lower than in the control cells (Figure 4C), further suggesting
that EBNA3C is required for maintenance of Gemin3 levels. To
determine if the increased production of Gemin3 is due to post-
translational regulation by EBNA3C, we co-expressed exogenous
EBNA3C-FLAG with GFP-Gemin3 or GFP control vector into
Saos-2 cells and determined the protein levels of GFP-Gemin3 and
GFP. The results showed that the production of GFP-Gemin3 but
not GFP was enhanced by EBNA3C in a dose-dependent manner
(Figure 4D, left and middle panels), indicating that the interaction
of EBNA3C with Gemin3 is important for Gemin3 accumulation.
To this end, we carried out similar experiments by using an
Figure 2. EBNA3C colocalizes with Gemin3. (A) Colocalization of exogenous E3C and Gemin3 in U2OS cells. Cells transfected with E3C-FLAG and
GFP-Gemin3 were stained by using M2 antibody, followed by goat anti-mouse antibody conjugated to Alexa Fluor 594 (red). (B) Endogenous Gemin3
colocalizes with E3C in the EBV-transformed cell line LCL1. Endogenous Gemin3 and E3C were individually detected by using mouse anti-Gemin3
(12H12) and rabbit anti-E3C antibodies, followed by Goat anti-mouse antibody conjugated to Alexa Fluor 594 (red) and goat anti-rabbit antibody
conjugated to Alexa Fluor 488 (green). Nuclei were counterstained by using DAPI (blue). The images were sequentially captured using an Olympus
confocal microscope. All panels are representative pictures from similar repeat experiments. Enlarged sections are shown at the bottom. Arrows show
the colocalization of E3C and Gemin3.
doi:10.1371/journal.ppat.1002418.g002
EBNA3C Stabilizes Gemin3
PLoS Pathogens | www.plospathogens.org 3 December 2011 | Volume 7 | Issue 12 | e1002418EBNA3C mutant lacking Gemin3-interacting domain, and found
that deletion of the Gemin3-interacting domain efficiently
abolished the effect of EBNA3C on Gemin3 production
(Figure 4D, left and right panels). To further confirm that
EBNA3C-induced Gemin3 levels were due to enhanced Gemin3
protein stability, we performed the protein stability assays for
Gemin3 by treating BJAB (EBNA3C negative) and BJAB10
(EBNA3C positive) cells with cycloheximide (a protein translation
inhibitor). The results showed that the stability of Gemin3 was
dramatically enhanced in the presence of EBNA3C compared to
cells without EBNA3C (Figure 4E).
Gemin3 interacts with p53 and contributes to EBNA3C-
mediated inhibition of p53 transcriptional activity
Our previous studies showed that EBNA3C blocks p53-
mediated transcriptional as well as apoptotic activity [22],[34].
Gemin3 plays an essential role in cell survival and can function as
a transcriptional repressor through interaction with a number of
transcriptional factors [35],[36]. Therefore, we hypothesized that
EBNA3C enhanced Gemin3 levels may be due to its interaction
with p53 and in turn repress the transcriptional activity of p53. To
this end, we first asked if Gemin3 can directly bind to p53 in vitro.
Using in vitro-translated Gemin3, we incubated it with bacterially
Figure 3. EBNA3C and Gemin3 interact through their C-terminal domains. (A) and (B) Gemin3 associates with the C-terminal domain of
EBNA3C. Twenty million of HEK 293 cells were cotransfected with plasmids expressing GFP-tagged Gemin3 and Flag-tagged either full-length or the
truncated mutants of EBNA3C. At 36 h post-transfection, cells were harvested and subjected to immunoprecipitation using anti-FLAG (M2) or GFP
antibodies followed by western blotting with GFP or M2 antibody. 5% of whole cell lysates (WCL) were used as input. The membrane was stripped
and reblotted with M2 or GFP antibody. (C) Gemin3 binds to C-terminal domain of E3C in vitro. The
35S-radiolabeled in vitro-translated proteins of
E3C truncated mutants were precleared with GST bead, followed by incubation with GST or GST-Gemin3 beads. The bound protein mixtures were
resolved by appropriate SDS-PAGE, and autography. 5% of in vitro translated protein is used as input. The quantification of relative amount of bound
protein (RBU) was shown at the bottom. (D) The
35S-radiolabeled in vitro-translated protein full-length Gemin3 was pulled down by truncated
mutants of EBNA3C fusion with GST (GST-E3C 1–365, 366–581,582–792, and 900–992). Coomassie blue staining of purified GST-EBNA3C truncated
proteins is shown at the bottom panel. (E) E3C binds to C-terminal domain of Gemin3 in vitro. The
35S-radiolabeled in vitro-translated protein full-
length EBNA3C was pulled down by truncated mutants of Gemin3 fusion with GST (GST-Gemin3 1–272, 307–547, and 546–825). Coomassie blue
staining of purified GST-Gemin3 truncated proteins is shown at the bottom. (F) Schematics illustrate different structural domains of E3C and Gemin3.
The respective binding domain(s) of two proteins are indicated by bold.
doi:10.1371/journal.ppat.1002418.g003
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strongly bound to p53 but not the GST control (Figure 5A, lane 2
and 3). Using different truncation mutants of p53 fusion with
GST, we found that the DNA-binding domain (amino acids 100–
300) of p53 is critical for interaction with Gemin3 (Figure 5A, lane
4 to 6). To define the binding site of Gemin3 with p53, we utilized
full length and truncated mutants of Gemin3 fusion with GST to
incubate with in vitro-translated p53. The results showed that the
C-terminal domain (amino acids 546–825) alone of Gemin3
presents similar strong binding with p53 as full length Gemin3
(Figure 5B). This further confirms that Gemin3 can directly
interact with p53. To test if endogenous p53 interacts with
Gemin3 in cells and whether this interaction is impaired by
EBNA3C, we performed immunoprecipitation assays with anti-
p53 antibody followed by western blotting with Gemin3 antibody
individually from cell lysates of BJAB, BJAB10 and LCL1 cells.
The results showed that Gemin3 and p53 do form a complex in
EBV negative BJAB cells, and that the association of p53 with
Gemin3 was greatly enhanced by 2.2 fold in EBNA3C-expressing
BJAB10 cells and 5.2 fold in LCL1 cells when compared to that in
the EBV negative BJAB cells (Figure 5C, bottom panel). Since
Gemin3 bound to the DNA-binding domain of p53, we wanted to
Figure 4. EBNA3C enhances the protein stability of Gemin3. (A) and (B) E3C increases the protein production of endogenous Gemin3. Ten
million of EBV negative cells (Ramos, BJAB and PBMC), EBNA3C- expressing cells (BJAB7 and BJAB10), and EBV-transformed cells (LCL1 and LCL2) were
lysed and subjected to western blot with indicated antibodies. The data show that the protein level of Gemin3 in the EBNA3C or EBV positive cells
was significantly upregulated. (C) The protein level of Gemin3 is decreased in BJAB10 and LCL1 cells with EBNA3C stable knockdown. BJAB10 and
LCL1 cells with Lentivirus-delivered GFP labeled shRNA against EBNA3C (shE3C) or scramble control (shCtrl) were showed on the left panel. The
protein levels of E3C and Gemin3 are detected by western blotting with indicated antibodies. GAPDH immunoblotting was used as the loading
control. The relative quantitation of Gemin3 and E3C protein levels are normalized by GAPDH. (D) E3C increases the protein level of exogenous
Gemin3. Saos-2 cells were transfected GFP-Gemin3 or GFP with increasing amounts of full length (FL) EBNA3C-FLAG or its C-terminal deleted mutant
(DC). The transiently transfected cells were harvested at 36 h post-transfection, the protein levels of exogenous GFP-Gemin3 and GFP were detected
by western blotting with GFP antibody. The relative quantitation of GFP-Gemin3 or GFP is shown in the middle panel. (E) EBNA3C enhances the
protein stability of Gemin3. The cell lysates of BJAB or BJAB10 cells treated with cycloheximide (CHX, 100 mg/ml) for 0, 2, 4 and 6 hours were
subjected to immunoblotting as indicated. GAPDH immunoblotting was used as the loading control. The relative quantitation of Gemin3 is shown in
the middle panel.
doi:10.1371/journal.ppat.1002418.g004
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p53, and so performed chromatin immunoprecipitation assays
with exogenous p53 alone or p53 and Gemin3 in the presence and
absence of p53-responsive DNA element (p53-RE). As shown in
the Figure 5D, Gemin3 dramatically reduced the ability of p53 to
bind to the p53-responsive DNA element. To further confirm the
consequence of Gemin3 blocking DNA-binding ability of p53 and
argue the possibility that Gemin3 can directly bind to DNA probe,
we also performed reporter assays by co-expressing exogenous
HA-p53 with increasing doses of GFP-tagged Gemin3 in the
presence of 13 copies of p53-binding sites driven luciferase
reporter into p53-null Saos-2 cells. The results showed that
Figure 5. Gemin3 interacts with p53 and contributes to EBNA3C-mediated inhibition of p53 transcriptional activity. (A) Gemin3 binds
with DNA-binding domain of p53 in vitro.
35S-radiolabeled Gemin3 was in-vitro translated and incubated with bacterially purified GST, GST fusion
with full length (1–393) or truncated mutants of p53 (1–83, 100–300, and 300–393). The pull-down complexes were resolved by appropriate SDS-
PAGE and autography. The amount of bound protein was quantified with ImageQuant software. Coomassie blue staining of purified GST protein is
shown in the middle panel. Schematic illustrates the binding domains of p53 with Gemin3 and EBNA3C. (B) C-terminal domain of Gemin3 binds with
p53 in vitro.
35S-radiolabeled p53 was in vitro translated and incubated with bacterially purified GST control, full length GST-Gemin3 (1–825) or its
truncations (1–272, 307–547, and 546–825). The GST pull down assay was analyzed as the described above. (C) EBNA3C increases the interaction of
p53 with Gemin3. Twenty million of BJAB, BJAB10 and LCL1 cells were individually harvested, lysed and subjected to immunoprecipitation (IP) with
p53 specific antibody and subsequently western blotted with Gemin3 or p53 antibody. The relative quantitation of Gemin3 complex with p53 was
calculated by IP compared with input and shown in bottom panel. (D) Gemin3 reduces DNA-binding affinity of p53. Saos-2 cells were co-transfected
HA-p53 with or without GFP-Gemin3 in the presence of p53-RE-Luc containing 13 copies of p53-binding sties or pGL3-basic vector alone. Chromatin
immunoprecipitation assays were performed with anti-HA or normal lgG antibodies control. The DNA binding ability of p53 was detected by
standard (upper) and quantitative real-time (lower) PCR with primers targeting ampicilin gene of pGL3 plasmid. (E) Gemin3 inhibits the transcriptional
activity of p53 in the luciferase reporter assay. Saos-2 cells were co-transfected with 3 mg of the pGL3-p53-RE-Luc, 10 mg HA-p53 in the presence of
either vector control or increasing amounts of GFP-Gemin3 (5 mg and 10 mg). Each transfection was performed in triplicate. Error bars indicated
standard variations. Bottoms panels show the protein levels detected by western blotting analysis with the indicated antibodies. GAPDH was used as
a control for equal loading. The relative luciferase unit (RLU) is showed by normalization with vector alone. (F) Gemin3 knockdown reduces E3C-
mediated inhibition of p53 transcriptional activity in the luciferase reporter assays. Saos-2 cells with stable Gemin3 knockdown (shG3) or control
(shCtrl) were individually co-transfected p53-RE-Luc with HA-p53, HA-p53 and E3C-FLAG or vector alone. The western blotting data of each protein is
shown at the bottom panel. The relative luciferase unit (RLU) is showed by normalization with vector alone. Plasmid expressing RFP was used for
normalized transfection efficiency.
doi:10.1371/journal.ppat.1002418.g005
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dose-dependent manner (Figure 5E). The expression levels of
Gemin3, p53, and GAPDH as a loading control, were also
analyzed by western blotting (Figure 5E, bottom panels). To
answer if EBNA3C-mediated inhibition of p53 transcriptional
activity is dependent on Gemin3 accumulation, we performed
similar reporter assays by co-expressing p53 with or without
EBNA3C in the presence of specific Gemin3 shRNA (shG3) or
non-specific control shRNA (shCtrl). Strikingly, the results showed
that EBNA3C-mediated inhibition of p53 transcriptional activity is
dramatically reversed once Gemin3 is knocked down (Figure 5F,
compare lane 3 with 6). This suggests that Gemin3 is important for
EBNA3C-mediated inhibition of p53 function.
Gemin3 knockdown attenuates EBNA3C-mediated
inhibition of p53-induced apoptosis
Studies in our lab have shown that EBNA3C is able to inhibit
p53-induced apoptosis in p53-null Saos2 cells [22],[34]. To further
confirm the significance of Gemin3 on EBNA3C-mediated
inhibition of p53 function, we verified whether or not Gemin3
knockdown affects EBNA3C-mediated inhibition of p53-induced
apoptosis by using colony formation assays. The results showed
that coexpression of EBNA3C with p53 markedly increased the
colony formation of Saos-2 cell compared to that produced by p53
alone (Figure 6A, left panel). In contrast, although less colony
formation was produced in the vector alone with the Gemin3
knockdown (shG3) compared to that with the control knockdown
(shCtrl) (Figure 6A, top panel), the colony formation of p53 co-
expressed with EBNA3C was significantly inhibited in Gemin3
knockdown cells (Figure 6A). Thus, these data revealed a role for
EBNA3C in upregulation of Gemin3 for anti-apoptosis and
promotes cell proliferation.
To further prove that Gemin3 plays an important role in cell
proliferation, we performed apoptosis assays using B lymphoma
cells or LCLs with or without lentivirus-mediated Gemin3
knockdown. Gemin3 expression was significantly knocked down
in the EBV negative B lymphoma cell lines Ramos and BJAB, EBV
transformed B cell line LCL1 as well as EBNA3C stably expressing
BJAB cell lines BJAB7 and BJAB10 (Figure 6B). The results of
apoptotic assays showed that Gemin3 knockdown cells had a
dramatic increase in apoptosis compared to the control knockdown
cells (Figure 6C). Furthermore, Gemin3 knockdown in EBV or
EBNA3C positive cells showed significantly higher levels of
apoptosis than that in EBV or EBNA3C negative cells (Figure 6C,
bottom panel). Consistently, the quantitative PCR analysis showed
that the transcriptional levels of p53 downstream genes including
p21, Bax and p53 were enhanced when Gemin3 was knocked down
in EBNA3C positive cells and were remarkably higher than that in
EBNA3C negative cells (Figure 6D). Therefore, Gemin3 plays a
critical role in cell proliferation in EBNA3C positive cells.
Discussion
Emerging evidence have indicated that Gemin3 is an essential
gene for embryonic development and survival from mammal to
Drosophila [23],[37]. Gemin3 (DP103/DDX20) was originally
discovered in a screen for cellular factors that bind to EBNA2 and
EBNA3C using the yeast two-hybrid system [24]. Gemin3 was
shown to be involved in EBNA2-mediated transactivation and
transformation, and a deletion mutant of EBNA2 lacking the
Gemin3-binding site severely impeded LMP1 transactivation and
viral transformation [26]. However, there was no previous report
on the functional effect of EBNA3C on Gemin3. Our yeast two-
hybrid screen showed that Gemin3 strongly interacted with
EBNA3C and this was identified with high frequency in positive
yeast clones when the C-terminal domain of EBNA3C was used as
bait (data not shown). We now confirm that Gemin3 directly binds
to EBNA3C in vitro and in vivo, and this interaction led to
increased Gemin3 protein stability and its accumulation in B
lymphoma cells and EBV-transformed lymphoblastoid cell lines.
Furthermore, EBNA3C promoted the formation of a complex
with p53 and Gemin3 in vivo which was important for blocking
p53-mediated transcriptional activity and apoptosis. Inhibition of
Gemin3 expression dramatically abolished EBNA3C-mediated
inhibition of p53-induced apoptosis (Figure 7). The emerging
evidence showing Gemin3 as a DEAD-box RNA helicase that
plays a role in carcinogenesis, will inspire us to develop efficient
helicase inhibitors as a potential target for anti-cancer in the
future.
Gemin3 is also an integral component of the SMN complex,
which plays an essential role in the production of spliceosomal
small nuclear ribonucleoproteins (snRNPs) [38], regulation of
DNA transcription [30], pre-mRNA splicing [37], and axonal
RNA transport [39]. In addition to interaction with Gemin3,
EBNA3C also has been shown to associate with SMN [25]. This
further supports the notion that EBNA3C targets the SMN
complex and can impair the function of each component including
Gemin3 in the SMN complex. Here, we demonstrate a novel
function of Gemin3 as a regulator that suppresses p53-mediated
transcriptional activity and apoptosis. Interestingly, SMN was also
shown to interact with p53 [40]. Therefore, our results showing
that knockdown of Gemin3 sufficiently rescues p53, suggest that
Gemin3 could be a critical member of the SMN complex to
suppress p53 function. This provides an explanation as to why
EBNA3C promotes complex formation of p53 and Gemin3
through enhancing Gemin3 protein stability.
The N-terminal domain of Gemin3 contains the conserved
helicase motifs, while the non-conserved C-terminal domain can
interact with a variety of cellular and viral factors. In this study, we
found that Gemin3 binds with both EBNA3C and p53 through
the same region (amino acid 548 to 825) of its C-terminal domain.
Considering that EBNA3C individually binds to p53 and Gemin3
through its N-terminal and C-terminal domains. There is a strong
possibility for EBNA3C to act as an adaptor to promote Gemin3
interaction with p53. This also may provide an explanation as to
why the levels of p53 in complex with Gemin3 are dramatically
enhanced in the presence of EBNA3C.
Although it has been shown that Gemin3 plays a diverse roles
on repressing gene transcription [30], the mechanism of Gemin3-
mediated transcriptional repression is not fully clear. One of the
potential mechanisms could be through recruitment of specific
transcription co-repressors. For examples, Gemin3 interacts with
METS to repress Ets by assembling a complex of N-CoR, Sin3A,
HDAC-2, and HDAC-5 [30],[33],[41]. Gemin3 was also found to
form a complex with METS (mitogenic Ets transcriptional
suppressor)/PE1 or ERF (Ets2 repressor factor) controlling cellular
proliferation and differentiation through recruitment of HDAC2 and
HDAC5 [42]. It also interacts with and represses the transcriptional
activity of Egr2/Krox-20 which is dependent in part on HDAC
recruitment [31]. Gemin3 also interacts with the transcriptional
factor FOXL2 important for inducing apoptosis [32]. However, our
study showed that Gemin3 reduces p53 transcriptional activity and
now provides another potential mechanism through which Gemin3
can sequester a transactivation cofactor or may disrupt a transcrip-
tionally active nucleic acid-protein complex.
Previous studies in our lab indicated that EBNA3C targets
multiple factors to deregulate the p53 pathway and so drive cell
proliferation. For example, EBNA3C has a unique activity of
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suppresses p53 function through formation of a complex with
Mdm2 [21]. More recently, our lab also showed that EBNA3C
directly competes with two p53-associated growth inhibitors ING4
and ING5 for attenuating p53 function [34]. Despite current
studies which convincingly showed that EBNA3C inhibit p53
function, it is still unknown as to why the protein level of p53 is not
affected in EBV-transformed LCLs or in B lymphoma expressing
EBNA3C [43–46]. Here, our study further addresses a potential
mechanism that EBNA3C can block p53 function through
upregulating Gemin3 protein levels and so promoting the
formation of a complex of p53 with Gemin3. This is distinctly
different from the strategy used by KSHV encoded LANA where
p53 ubiquitylation is induced and results in its degradation [47]. In
summary, this study provides initial evidence that Gemin3 can
directly interact with p53 through its DNA-binding domain and in
turn inhibits its activities. This pathway is essentially targeted by
EBNA3C in EBV-transformed lymphoblastoid cells.
Materials and Methods
DNA constructs and antibodies
pA3F-EBNA3C constructs expressing either full-length EB-
NA3C or different truncated versions of EBNA3C 1–365, 366–
620, and 621–992 with a Flag tag at the carboxy-terminal end and
Glutathione S-transferase (GST)-EBNA3C truncation mutation
were described previously [20]. Constructs expressing green
fluorescent protein (GFP)-tagged Gemin3 was prepared by cloning
PCR-amplified fragments into pEGFP-C1 vector (BD Biosciences
Clontech) at EcoRI and SalI restriction sites. The plasmid pGL3-
Figure 6. Gemin3 knockdown attenuates EBNA3C-mediated inhibition of p53-induced apoptosis. (A) Saos-2 (p53
2/2) cells were
electroporated with different combinations of expression plasmids for HA-p53, EBNA3C-FLAG or vector alone in the presence of small hairpin RNA
against Gemin3 (shG3) or control (shCtrl) as indicated. 2610
3 transfected cells were cultured in the selection medium (DMEM supplemented with
100 mg/ml G418). After a 2-week selection, cells were fixed on the plates with 4% formaldehyde and stained with 0.1% crystal violet. The area of
colonies (pixels) in each dish was calculated by LiCor Odyssey. The number represents the averages of data from two independent experiments.
Plasmid expressing RFP was used for normalized transfection efficiency. (B) Western blots showing the protein level of Gemin3 in the lentivirus-
mediated Gemin3 or control knockdown cell lines. GAPDH was used as the loading control. (C) Gemin3 knockdown increases apoptosis of EBV
negative cells (Ramos and BJAB), EBNA3C positive cells (BJAB7 and BJAB10), and EBV transformed cells (LCL1). Cells were harvested after a 12-h serum
starvation and fixed. Levels of cells undergoing apoptosis (sub-G1 phase) in individual PI-stained samples were detected by flow cytometry, and the
data were analyzed by FlowJo software. The bar diagram shown at the bottom panel represents the mean of three independent experiments and the
results of comparing with each control knockdown sample. (D) Quantitative real-time PCR analysis showed that p53, p21 and Bax genes were
upregulated in the Gemin3 knockdown cells. Total RNA was individually isolated from the Gemin3 (shG3) or control (shCtrl) knockdown cells with 12-
h serum starvation treatment. A 2 mg total RNA was used to synthesis cDNA. Error bars show standard deviations.
doi:10.1371/journal.ppat.1002418.g006
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firefly luciferase gene was constructed by EcoRV insertion of p53-
binding sequences into the pGL-3 luciferase reporter plasmid
(Kindly provided by Wafik S. EI-Deiry at University of Pennsylva-
nia, Philadelphia, Pennsylvania). pGEX-p53 expresses an N-
terminal glutathione S-transferase (GST)-p53 fusion protein was
derived from pGEX-2T (Amersham Pharmacia, Inc, Piscataway,
NJ) by insertion of human p53 cDNA (A gift from Gary J Nabel,
National Institutes of Health, Bethesda, MD) at the BamH1 and
EcoR1 sites. pcDNA-HA-p53 was generated by cloning PCR-
amplified p53 cDNA using pGEX-p53 as a template into the
pcDNA3-HA vector at EcoR1 and Not1 sites. GST-p53 truncation
mutants were constructed by insertion of PCR fragments into the
pGEX-5x-1 backbone (gift from Shelley L Berger, The Wistar
Institute, Philadelphia, PA). Plasmid expressing GST-Gemin3 was
kindly provided by Dr. Gideon Dreyfuss (Howard Hughes Medical
Institute Investigator at University of Pennsylvania Perelman
School of Medicine) and described previously [23]. GST-Gemin3
truncation mutants GST-Gemin3 1–272 was constructed by
insertion of PCR fragments into pGEX-2TK derivative vector at
Kpn1a n dEcoR1 sites, GST-Gemin3 307–547 and GST-Gemin3
546–825 into pGEX-2TK vector BamH1 and EcoR1 sites. All
constructs and mutations were verified by DNA sequencing.
Mouse monoclonal anti-Gemin3 (12H12) was kindly provided by
Dr. Gideon Dreyfuss (Howard Hughes Medical Institute Investiga-
tor at University of Pennsylvania School of Medicine). The
monoclonal antibodies mouse anti-myc (9E10) and anti-EBNA3C
(A10) were prepared from the respective hybridoma cultures. Mouse
monoclonal antibody anti-FLAG epitope (M2) was purchased from
Sigma-Aldrich Corp. (St. Louis, MO). Mouse monoclonal antibody
reactive to p53 (DO-1) and GFP (F56-BA1) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Cell culture and transfection
Human embryonic kidney cells transformed with sheared
adenovirus type 5 DNA HEK293 cell line and p53-null cell line
SaoS-2 were obtained from Jon Aster (Brigham and Woman’s
Hospital, Boston, MA) [48]. U2OS is also a human osteosarcoma
cell line [49]. EBV negative Burkitt’s lymphoma cell lines BJAB
and Ramos were provided by Elliott Kieff (Brigham and Woman’s
Hospital, Boston, MA) [50]. LCL1 and LCL2 are in vitro-
transformed EBV positive cell lines. BJAB cells expressing
EBNA3C (BJAB7 and BJAB10) were generated previously by
transfecting with pZipneo eukaryotic expression vector with
EBNA3C cDNA followed by neomycin selection [51]. HEK
293, U2OS and Saos-2 cells were grown in Dulbecco’s modified
Eagle’s medium (purchased from HyClone, Logan, UT) supple-
mented with 10% fetal bovine serum, 50 U/ml penicillin, 50 mg/
ml streptomycin, and 2 mM L-glutamine. BJAB, Ramos and the
EBV-positive cell lines were maintained in RPMI 1640 medium
(HyClone, Logan, UT) supplemented as described for Dulbecco’s
modified Eagle’s medium above. All cultures were incubated at
37uC in a humidified environment supplemented with 5% CO2.
Cells were transfected by electroporation with a Bio-Rad Gene
Pulser II electroporator. Briefly, 15610
6 cells harvested in
exponential phase were collected, washed in phosphate-buffered
saline (PBS), and resuspended in 400 ml of the appropriate
medium containing DNA for transfection [52]. Resuspended cells
were transferred to a 0.4-cm-gap cuvette, and electroporation was
performed at 975 mF, 210 V for HEK293 and Saos-2 cells.
Transfected cells were transferred to a 100-mm petri dish
containing 10 ml of complete medium and incubated at 37uC.
Immunoprecipitation and Western blotting
Transfected cells were harvested, washed with ice-cold PBS, and
lysed in 0.5 ml ice-cold radioimmunoprecipitation (RIPA) buffer
(1% Nonidet P-40 [NP-40], 10 mM Tris [pH 7.5], 2 mM EDTA,
150 mM NaCl), supplemented with protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml pep-
statin, and 1 mg/ml leupeptin). Cell debris was removed by
centrifugation at 21,0006g (10 min and 4uC), and the supernatant
was transferred to a fresh microcentrifuge tube. Lysates were then
precleared by end-over-end rotation with normal mouse serum
and 30 ml of a 1:1 mixture of Protein A-Protein G-conjugated
Sepharose beads (1 h, 4uC). Beads were spun out, and supernatant
was transferred to a fresh microcentrifuge tube and approximately
5% of the lysate was saved for input control. The protein of
interest was captured by rotating the remaining lysate with 1 mgo f
appropriate antibody overnight at 4uC. Immune complexes were
captured with 30 ml of a 1:1 mixture of Protein A and Protein G
Sepharose beads, pelleted, and washed five times with ice-cold
RIPA buffer. For Western blot assays, input lysates and
immunoprecipitated (IP) complexes were boiled in Laemmli buffer
[53], fractionated by SDS-PAGE, and transferred to a 0.45 mm
nitrocellulose membrane. The membranes were then probed with
appropriate antibodies followed by incubation with appropriate
infrared-tagged secondary antibodies and viewed on an Odyssey
imager (LiCor Inc., Lincoln, NE).
Purification of GST fusion proteins
Escherichia coli BL21 (DE3) cells were transformed with the
plasmid constructs for each GST fusion protein. Single colonies
were picked and grown overnight in 3 ml of Luria broth
supplemented with 100 mg/ml ampicillin. One milliliter of the
overnight culture was used to inoculate a 500 ml culture. The
larger culture was incubated until the optical density at 600 nm
was approximately 0.6, at which point it was induced with 1 mM
Figure 7. A schematic model depicting the Gemin3-mediated
transcriptional regulation of p53 by EBNA3C in the EBV
latently infected cells. Left panel, in response to genotoxic stress,
p53 achieves its anti-proliferative properties through its function as a
DNA-binding transcriptional activator, and induce expression of
downstream target genes (including p21 and BAX) for cell-cycle arrest
and apoptosis. Right panel, in the EBV latency III cells, EBNA3C not only
stabilizes Gemin3 through the interaction of their C-terminal domains
and but also enhances a stable complex of Gemin3 with p53 for
blocking p53-mediated transcriptional activity and cell apoptosis.
Gemin3 knockdown (siRNA) increases the sensitivity of the EBNA3C-
expressing cells to stress-induced apoptosis. p53-RE, p53 responsive
element.
doi:10.1371/journal.ppat.1002418.g007
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The bacteria were pelleted, washed once with STE buffer
(100 mM NaCl, 10 mM Tris, and 1 mM EDTA, pH 7.5),
resuspended in 3 ml NETN buffer (0.5% NP-40, 100 mM NaCl,
20 mM Tris, 1 mM EDTA, pH 8.0), supplemented with protease
inhibitors, and incubated on ice for 15 min. A volume of 150 mlo f
1 M dithiothreitol (DTT) and 1.8 ml of a 10% solution of Sarkosyl
in STE buffer was added, and the suspension was sonicated (for
3 min on ice) to solubilize the proteins. The lysates were
centrifuged (12,0006g, 10 min, 4uC) to separate the unsolubilized
fraction. The clear supernatant was transferred to a fresh tube, to
which 3 ml of 10% Triton X-100 in STE buffer and 200 mlo f
Glutathione-Sepharose beads were added. The tube was rotated
overnight at 4uC, after which the purified protein bound to
Glutathione was collected by centrifugation (2 min, 6006g, 4uC)
and washed five times with NETN buffer supplemented with
protease inhibitors. The level of purification was determined by
SDS-PAGE, and purified proteins were stored at 4uC.
GST pull-down assays
For pull-down assays from cell lysates, lysates were prepared in
RIPA buffer (0.5% NP-40, 10 mM Tris [pH 7.5], 2 mM EDTA,
150 mM NaCl, supplemented with protease inhibitors). Lysates
were precleared and then rotated with either GST control or the
appropriate GST fusion protein bound to Glutathione-Sepharose
beads. For in vitro binding experiments, GST fusion proteins were
incubated with
35S-labeled in vitro-translated protein in binding
buffer (16PBS, 0.1% NP-40, 0.5 mM DTT, 10% glycerol,
supplemented with protease inhibitors). In vitro translation was
performed with the T7-TNT Quick Coupled transcription-
translation system (Promega Inc., Madison, WI) according to the
manufacturer’s instructions.
Immunofluorescence
To check the co-localization of ectopically expressed GFP-
Gemin3 and Flag-EBNA3C in the cells, we used Lipofectamine
2000 (Invitrogen, Carlsbad, CA) to transfect U2OS cells with the
plasmids then cultured on coverslips. At 36 h posttransfection,
cells were fixed using 3% paraformaldelhyde with 0.1% Triton X-
100 for 20 min at room temperature. We used LCL1 cells to
examine the co-localization of endogenous Gemin3 with EB-
NA3C, appropriate LCL1 cells were added onto slides and fixed
using the same method after culture 5 h. Fixed cells were washed
with PBS and subsequently blocked in 1% BSA for 10 min.
Gemin3 was detected using mouse monoclonal antibody (12H12).
Endogenous EBNA3C was detected using EBNA3C-reactive
rabbit polyclonal antibody (1:150 dilution); Flag-tagged EBNA3C
was detected using M2 antibody (1:1,000 dilution; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). Primary antibodies were
incubated with the cells for 60 min at the room temperature. Cells
were washed three times with PBS and exposed to secondary
antibodies. Goat anti-mouse antibody conjugated to Alexa Fluor
594 to detect Gemin3 and goat anti-rabbit antibody conjugated to
Alexa Fluor 488 to detect EBNA3C were respectively used for
LCL1 cells, and Goat anti-mouse antibody conjugated to Alexa
Fluor 594 to detect FLAG-EBNA3C was used for U2OS cells.
Secondary antibodies were diluted in blocking buffer at 1:1,000
and incubated for 1 h at RT, followed by three washes with
blocking buffer. The last wash contained 49,6 9-diamidino-2-
phenylindole (DAPI; Promega, Madison, WI) to counterstain the
nuclei. The slides were examined using Olympus confocal
microscopy and the images were analyzed with a Fluoview
FV300 (Olympus, Melville, NY) software.
Luciferase reporter assay
Twelve million Saos-2 cells were co-transfected by using a Bio-
Rad electroporater (Bio-Rad Laboratories, Inc., Hercules, CA)
with different combination of pGL3-p53-RE, pcDNA-HA-p53,
pA3F-EBNA3C and GFP-Gemin3. At 24 h post-transfection, cells
were harvested, washed in PBS, and lysed by cell lysis buffer
(BioVision, Inc., Mountain View, CA). Forty microliters of cell
lysate was used for the reporter assay, using an LMaxII384
luminometer (Molecular Devices, Inc., Sunnyvale, CA). A portion
of the cell lysate was used for Western blotting. Transferred
proteins were detected with Odyssey infrared scanning technology
(LI-COR, Inc., Lincoln, NE), using Alexa Fluor 680 and Alexa
Fluor 800 (Molecular Probes, Carlsbad, CA, and Rockland,
Gilbertsville, PA, respectively). All the transfections were per-
formed multiple times, and the results shown represent the means
of the data from three independent experiments.
Lentiviral-mediated gene silencing
For the lentivirus-mediated knockdown of EBNA3C or
Gemin3, the EBNA3C shRNA sequence (CCAUAUACCG-
CAAGGAAUA) or Gemin3 shRNA (ACUCCCCAGUGAGAC-
CAUU) was respectively inserted into pGIPZ vector according to
the manufacture’s instructions (Open Biosystem, Inc, Huntsville,
AL), the vector expressing EBNA3C or Gemin3 small hairpin
RNA is abbreviated as shE3C or shG3, respectively. A 21-mer
oligonucleotide (UCUCGCUUGGGCGAGAGUAAG) that had
no significant homology to any known human mRNA in the
databases was cloned in the same vector and used as control.
Control shRNA is hereinafter abbreviated as shCtrl.
Lentiviruses were produced by transient transfection into HEK
293T cells as previously described with the following modifications
[54]. A total of 2610
6 293T cells were seeded in 10-cm-diameter
dishes in DMEM (HyClone, Logan, UT) supplemented with 10%
FBS and cultured for 24 h prior to transfection. A total 20 mgo f
plasmid DNA was used for the transfection of each dish, including
1.5 mg of envelope plasmid pCMV-VSV-G (catalog no. 8454;
Addgene, Inc., Cambridge, MA), 3 mg of packaging plasmid
pRSV-REV (catalog no. 12251 Addgene, Inc., Cambridge, MA),
5 mg of packaging plasmid pMDLg/Prre (catalog no. 12251
Addgene, Inc., Cambridge, MA), and 10.5 mg of lentiviral vector
plasmid. The precipitation was formed by adding the plasmids to a
final volume of 438 mlo fH 20 and 62 ml of 2 M CaCl2, mixing
well, adding 500 mlo f2 6HEPES-buffered saline, and then
incubating at room temperature for 30 min. Chloroquine was
added to the 10 ml of plated media with a final concentration of
25 mM at 5 minutes prior to transfection. The medium was
replaced after 12 h with DMEM supplemented with 10% FBS and
10 mM HEPES, and 10 mM sodium butyrate. The medium was
replaced again 10 hours later using DMEM supplemented with
10% FBS and 10 mM HEPES. The conditioned medium was
collected four times at 12 h interval, filtered through 0.45 mm
pore-size cellulose acetate filters, and stored on ice. The virus was
concentrated by spinning at 70,0006g for 2.5 h. The concentrated
virus was resuspended in RPMI then used to infect 10
6 cells in the
presence of 20 mM/ml Polybrene. After 72 h, add puromycin to
final concentration of 2 mg/ml for selection. GFP immunofluo-
rescence was assessed by using an Olympus IX71 microscope
filtered with 560-nm excitation and 645-nm emission filters.
Visible colonies were grown to 80% confluence in the presence of
2 mg/ml puromycin prior to western blot and apoptosis analysis.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) experiments were
done essentially as previously described with some modifications
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6) transfected HA-p53 with or
without GFP-Gemin3 in the presence of pGL-p53-RE or pGL3-
basic vector alone were cross-linked with 1.1% (v/v) formalde-
hyde, 100 mM NaCl, 0.5 mM EGTA, and 50 mM Tris-HCl
(pH 8.0) in growth medium at 37uC for 10 min, then at 4uC for
50 min. Formaldehyde was quenched by adding 0.05 vol 2.5 M
glycine. Fixed cells were washed with PBS, incubated for 15 min
in 15 ml of 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5 mM
EGTA, and 0.25% (v/v) Triton X-100, followed by 15 min in
15 ml of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM
EGTA, and 200 mM NaCl, and finally sonicated in 1 ml of
10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1%
(w/v) SDS plus 1 mM PMSF, 1 mg/ml aprotonin, leupettin, and
pestatin to an average fragment size of 300–500 bp. 20% of
solubilized chromatin extracts were saved for input followed with
cross-link reverse step, and the remaining were clarified by
centrifugation at 12,000 g, and diluted to 6 OD260 U/ml in IP
buffer [140 mM NaCl, 1% (w/v) Triton X-100, 0.1% (w/v)
sodium deoxycholate, 1 mM PMSF, 100 mg/ml salmon sperm
DNA, and 100 mg/ml BSA]; preincubated for 1 h at 4uC with
10 ml/ml 50% (v/v) Protein A-agarose (Invitrogen Life Technol-
ogies, Camarillo, CA) with normal mouse/rabbit sera; reconsti-
tuted in PBS, and washed several times in IP buffer. Aliquots
(600 ml) were incubated with 20 mg of each specific antibody for
overnight at 4uC. Immune complexes were separated into bound
and unbound complexes with protein A-agarose and cross-links
were reversed by treatment at 65uC overnight. After treatment
with RNase A and proteinase K, samples were extracted once with
phenol/chloroform, and the DNA was precipitated with 2 volumes
of ethanol. Precipitated DNA was pelleted, washed once with 70%
ethanol, dried, and resuspended in 100 ml of water. The DNA was
analyzed by quantitative PCR using Ampicilin primers (forward:
5’-CATCTTACGGATGGCATGAC-3’, reverse: 5’-CAACGAT-
CAAGGCGAGTTAC-3’).
Colony formation assay
Ten million of Saos-2 cells were typically transfected using
electroporation with different combinations of expression plasmids
as shown in the text. Transfected cells were cultured in the
selection medium (DMEM supplemented with 100 mg/ml G418).
After 14 days, cells were fixed on the plates with formaldehyde and
stained with 0.1% crystal violet. The amount of the colonies in
each dish was scanned by Li-Cor Odyssey and counted. The data
are presented as the average from two independent experiments.
Quantitative real-time PCR
Total RNA from cells was extracted using Trizol reagent and
cDNA was made with a Superscript II reverse transcription kit
(Invitrogen, Inc., Carlsbad, CA). The primers for real-time PCR
were as followings: for p53: 59-CCT GAGGTTGGCTCTGAC-
TGTA-39(sense) and 59-TCCGTCCCAGTAGATTACCAC- 39
(antisense), yielding a 136-bp product; for p21: 59-GAGGGCAAG-
TACGAGTGG CAA-39 (sense) and 59- CTGCGCATTGCTC-
CGCTAACC-39 (antisense), yielding a 170-bp product; for Bax: 59-
TGCTTCAGGGTTTCATCCAGGA-39 (sense) and 59- ACGG-
CGGCAATCATCCTCTG-39 (antisense), yielding a 172-bp pro-
duct; and for GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase): 59-CTCCTCTGACTTCAAC AGCG-39 (sense) and 59-
GCCAAATTCGTTGTCATACCAG-39 (antisense), yielding a
112-bp product. The cDNA was amplified by using 10 ml of Master
Mix from the DyNAmo SYBR green quantitative real-time PCRkit
(MJ Research, Inc.), 1 mM of each primer, and 2 ml of the cDNA
product ina 20 ml total volume. Thirty cyclesof 1 min at 94uC, 30 s
at 55uC, and 40 s at 72uC were followed by 10 min at 72uCi na n
MJ Research Opticon II thermocycler (MJ Research, Inc.,
Waltham, MA). A melting curve analysis was performed to verify
the specificities of the amplified products. The values for the relative
levels of change were calculated by the ‘‘delta delta threshold cycle’’
(DDCT) method and each sample were tested in triplicates.
Apoptosis assay
The apoptotic cells of stable Gemin3 and control knock down
cells were analyzed by propidium iodide (PI) flow cytometric assay,
which is based on the principle that DNA fragmentation and the
consequent loss of nuclear DNA content occurs at the late phase of
apoptosis. Briefly, 10
6 cells with serum starvation treatment of
0.1% serum for 12 h were collected and fixed with 100% ethanol
for 2 h at 4uC, washed with 1x phosphate-buffered saline (PBS),
and stained with 50 mg/ml propidium iodide (Sigma, St. Louis,
MO) and 1 mg/ml RNase for 1 hour in the dark at 4uC. The
stained cells were subseqeutly analyzed using FACSCalibur
cytometer (Becton Dickinson, San Jose, CA) and FlowJo Software
(Tree Star, Ashland, OR).
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